DR Reddy’s Shares Gain On Receiving EIR From The US FDA

Shares in Dr Reddy's gained after the company said it has received Establishment Inspection Report for its Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad.

"Further to our intimation dated February 28, 2020 with regard to the audit of our Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad, we would like to inform you that we have received the Establishment Inspection Report (EIR) from US FDA, for the above-referred facility, indicating closure of the audit," the company said in a statement to the exchanges.

The shares of the company were last trading at Rs 3,744, up 2 per cent in trade. The stock has hit a 52-week high of Rs 4142.